Novartis notifies about Phase III COMBI-I study to treat skin cancer

By Nikita Chaurasia  Date: 2020-08-24

Novartis notifies about Phase III COMBI-I study to treat skin cancer

Reportedly, Novartis made an announcement that the COMBI-I study in its third phase that does evaluation of investigational immunotherapy spartalizumab (PDR001), combined with the targeted therapies Mekinist (trametinib) and Tafinlar (dabrafenib) did not produce a primary result of progression-free, investigator-assessed survival.

As per the trusted sources, the trail was conducted on untreated patients with metastatic (Stage IV) BRAF V600 or unresectable (Stage IIIC) mutation-positive cutaneous melanoma, in comparison with Tafinlar + Mekinist treatment alone. Tafinlar and Mekinist are medicines prescribed in combination to treat patients with skin cancer- melanoma.

John Tsai, MD, Chief Medical Officer and Head of Global Drug Development at Novartis states that although the COMBI-I trial did not get to its primary outcome, the report’s analysis offers some important insights of its part like the investigational immunotherapy spartalizumab could possibly contribute to the future cancer therapy combinations. Besides this, it also highlights the significance of Tafinlar + Mekinist for these patients as estimated in the past.

He further added that Novartis is fully dedicated towards curing melanoma patients through ongoing study and they would continue to provide the approved combination therapy Tafinlar + Mekinist to patients across the globe.

He added that they at Novartis extend gratitude to the patients and investigators who took part in the COMBI-I study and claimed that their collaboration has raised understanding of spartalizumab and its potential role in future cancer treatments at Novartis.

Reportedly, COMBI-I study investigators and people at Novartis will continue to analyze the data to gain more information from the results, which are likely to be taken forward to a presentation at a future medical meeting.

Novartis continues to search for more uses of immunotherapy in cancer treatment, along with the latest ongoing development of spartalizumab, across a plethora of tumors.  

Source credits-

https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-evaluating-investigational-spartalizumab-pdr001-combination-tafinlar-mekinist-advanced-melanoma

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Netflix confirms producing fictionalized version of Spotify’s ascension

Netflix confirms producing fictionalized version of Spotify’s ascension

By Nikita Chaurasia

Over-the-top content streaming & production giant Netflix Inc. is reportedly working on an untitled series that tells the story of one of the most successful music streaming companies, Spotify Ltd. The six-part series, already listed on Netflix,...

Edtech Byju’s is now India’s highest-valued startup at USD 16.5 billion

Edtech Byju’s is now India’s highest-valued startup at USD 16.5 billion

By Nikita Chaurasia

Byju’s, the largest education technology company, has emerged as India’s highest-valued startup after a USD 340 million funding round involving investors such as UBS Group, Blackstone, and Zoom founder Eric Yuan among others. Recently, B...

LiDAR maker Hesai Photonics secures USD 300 million in Series D funding

LiDAR maker Hesai Photonics secures USD 300 million in Series D funding

By Nikita Chaurasia

Hesai Photonics Technology Co. Ltd., a leading Shanghai-based LiDAR company, has reportedly secured USD 300 million in a Series D funding round which was led by GL Ventures LLC, Xiaomi Corporation, Hillhouse Capital Group, Meituan, and CPE. The roun...

Tesla terminates production of its Model S Plaid + variant indefinitely

Tesla terminates production of its Model S Plaid + variant indefinitely

By Nikita Chaurasia

CEO Elon Musk justified Model S Plaid as good enough against its successor. The Model S Plaid + was touted to be Tesla’s flagship vehicle, with a range of around 519 miles. After unveiling for the first time last year, American EV maker T...

ByHeart concludes largest U.S. clinical trial for infant food product

ByHeart concludes largest U.S. clinical trial for infant food product

By Nikita Chaurasia

ByHeart Inc., a New-York based infant, and baby nutrition company, has recently announced the completion of the largest clinical trial for new infant formula in the past 25 years. With this move, the company is earmarked to be the 4th FDA registered,...